{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:00:18Z","timestamp":1765886418819,"version":"3.40.4"},"reference-count":29,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Introduction: To assess predictive ability of serum interferon-inducible protein 10 (IP10) and hepatitis B core antibody (anti-HBc) levels for virological relapse (VR) and hepatitis B surface antigen (HBsAg) loss after nucleos(t)ide analog (NA) discontinuation. Methods: In this multicenter prospective study, overall 139 patients were followed up for 24 months after NA discontinuation. Results: End of treatment (EOT) IP10 and anti-HBc were 29.2 (5.1\u201366.4) pg\/mL and 193.6 (136.9\u2013221.4) IU\/mL. EOT IP10 and anti-HBc were independent predictors for VR and HBsAg loss in Cox regression analysis. Cumulative rates of VR in patients with EOT IP10 &amp;gt; 26.99 pg\/mL was 31.9% (vs. 70.1%, hazard ratio [HR] 2.998, p &amp;lt; 0.001). Cumulative incidences of VR in patients with EOT anti-HBc \u2264141.35 IU\/mL was 49.1% (vs. 60.6%, HR 2.99, p &amp;lt; 0.001). Cumulative probabilities of VR was 16.7% in patients with EOT IP10 &amp;gt; 26.99 pg\/mL plus anti-HBc \u2264141.35 IU\/mL (vs. 73.6%, HR 6.464, p &amp;lt; 0.001). Cumulative probabilities of HBsAg loss in patients with EOT IP10 &amp;gt; 93.5 pg\/mL was 46.2% (vs. 4.7%, HR 10.94, p &amp;lt; 0.001). Cumulative probabilities of HBsAg loss in patients with EOT anti-HBc \u226478.42 IU\/mL were 47.1% (vs. 5%, HR 12.27, p &amp;lt; 0.001). Patients with EOT IP10 &amp;gt; 93.5 pg\/mL plus anti-HBc \u226478.42 IU\/mL had the highest 24-month cumulative HBsAg loss rate (53.8% vs. 4%, HR 16.83, p &amp;lt; 0.001). Conclusion: High EOT IP10 and low EOT anti-HBc levels were related to both lower risk of VR and higher probability of HBsAg loss. <\/jats:p>","DOI":"10.1159\/000533515","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T09:34:12Z","timestamp":1692178452000},"page":"922-931","source":"Crossref","is-referenced-by-count":1,"title":["IP10 and Anti-HBc can Predict Virological Relapse and HBsAg Loss in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Discontinuation"],"prefix":"10.1159","volume":"41","author":[{"given":"Yandi","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinjie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anlin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuemin","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29640"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14155"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13084"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01812-0"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30474"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.046"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14376"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13447"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.12.015"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308546"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12626"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.8"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1007-3418.2015.12.002"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6101(97)00015-4"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.158.11.5536"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.11.6236"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.08.023"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1866"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13211"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12434"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3731"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7150\/thno.10636"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.05.047"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2017.11.012"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14323"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004422"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7417\/CT.2015.1853"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.10.016"}],"container-title":["Digestive Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ddi\/article-pdf\/41\/6\/922\/4059514\/000533515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ddi\/article-pdf\/41\/6\/922\/4059514\/000533515.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:37:12Z","timestamp":1745422632000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000533515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,12,11]]},"published-print":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.1159\/000533515","archive":["Portico"],"relation":{},"ISSN":["0257-2753","1421-9875"],"issn-type":[{"type":"print","value":"0257-2753"},{"type":"electronic","value":"1421-9875"}],"subject":[],"published":{"date-parts":[[2023]]}}}